Kévin Bourcier

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan et al. · Nature Cancer · 2021 · 515 citations · Full text

Lymphoid Neoplasia, Cancer Immunosurveillance, Pd-l1 Expression +9

CTLA4Ig treatment in patients with multiple sclerosis

Vissia Viglietta, Kévin Bourcier, Guy J. Buckle et al. · Neurology · 2008 · 96 citations

Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial

Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan et al. · European Journal of Cancer · 2022 · 47 citations · Full text

Phase Ii Trial, Gastrointestinal Oncology, Medicine +11

REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort.

Sophie Cousin, Carine Bellera, Jean‐Philippe Guégan et al. · Journal of Clinical Oncology · 2020 · 36 citations

Immunology, Immunoediting, Pathology +23

Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme)

Élise Deluche, Tiffany Darbas, Kévin Bourcier et al. · Medical Oncology · 2020 · 11 citations · Full text